Merit Medical Systems, Inc.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): April 13, 2026

Merit Medical Systems, Inc.

(Exact name of registrant as specified in its charter)


Utah	0-18592	87-0447695
(State or other jurisdiction of	(Commission	(I.R.S. Employer
incorporation or organization)	File Number)	Identification No.)


1600 West Merit Parkway
South Jordan, Utah		84095
(Address of principal executive offices)		(Zip Code)

(801) 253-1600

(Registrant's telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, no par value	MMSI	NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure

The information contained in Item 7.01 of this Current Report on Form 8-K is being furnished by Merit Medical Systems, Inc. (“Merit”) to provide historical revenue information disaggregated by its new foundational and therapeutic product categories for the years ended December 31, 2025, 2024, 2023, and 2022, as well as quarterly revenue information for each of the three-month periods ended March 31, 2024 to December 31, 2025. Merit is providing this historical revenue information for the purpose of aiding period-over-period comparisons for the years and three-month periods indicated. The historical revenue information does not constitute a revision or restatement of Merit’s previously reported consolidated financial statements.

Merit’s revenue under the new product categories for the years ended December 31, 2025, 2024, 2023 and 2022, respectively, was as follows (unaudited, in thousands):


	Year Ended December 31,
	2025		2024		2023		2022
Foundational	$	1,028,540	$	964,100	$	926,253	$	862,375
Therapeutic		487,366		392,414		331,113		288,606
Total	$	1,515,906	$	1,356,514	$	1,257,366	$	1,150,981

Merit’s revenue under the new product categories for the three-month periods ended March 31, June 30, September 30, and December 31, 2025, compared to the corresponding periods of 2024, was as follows (unaudited, in thousands):


	Three-Month Period Ended
2025	March 31		June 30		September 30		December 31
Foundational	$	240,382	$	262,382	$	260,906	$	264,870
Therapeutic		114,969		120,080		123,251		129,066
Total	$	355,351	$	382,462	$	384,157	$	393,936


	Three-Month Period Ended
2024	March 31		June 30		September 30		December 31
Foundational	$	232,930	$	245,404	$	240,742	$	245,024
Therapeutic		90,578		92,599		99,103		110,134
Total	$	323,508	$	338,003	$	339,845	$	355,158

Merit is providing historical revenue information under each product category by product platform for the years ended December 31, 2025, 2024, 2023 and 2022. Such supplemental information is presented for the purpose of providing additional details regarding Merit’s current revenue categories. Merit does not intend to provide revenue information disaggregated by product platform on a recurring basis in future periods.

Merit’s revenue by product platform for the years ended December 31, 2025, 2024, 2023 and 2022, respectively, was as follows (unaudited, in thousands):


	Year Ended December 31,
	2025		2024		2023		2022
Foundational
Access	$	588,542	$	538,272	$	527,440	$	498,375
OEM		167,086		165,420		150,480		135,066
Procedural Solutions		124,717		117,198		114,233		116,763
Vascular Intervention		139,997		132,284		119,883		102,663
Other		8,198		10,926		14,217		9,508
Total Foundational		1,028,540		964,100		926,253		862,375

Therapeutic
Cardiac Therapies		93,357		49,436		36,415		33,632
Endoscopy		72,481		54,415		37,019		31,912
OEM		40,464		39,886		42,681		38,079
Oncology		96,805		86,940		77,761		67,406
Renal Therapies		52,802		48,980		36,547		21,826
Vascular Intervention		131,457		112,757		100,690		95,751
Total Therapeutic		487,366		392,414		331,113		288,606

Total	$	1,515,906	$	1,356,514	$	1,257,366	$	1,150,981

The information contained in this Item 7.01 of this Current Report is furnished pursuant to General Instruction B.2. of Form 8-K and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing made by Merit under the Securities Act of 1933, as amended (the “Securities Act”), or the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits


EXHIBIT NUMBER		DESCRIPTION

104		The cover page from this Current Report on Form 8-K, formatted in Inline XBRL


	MERIT MEDICAL SYSTEMS, INC.


Date: April 13, 2026	By:	/s/ Brian G. Lloyd
		Brian G. Lloyd
		Chief Legal Officer and Corporate Secretary